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Identification and Characterization
of a Homozygous Deletion Found in Ovarian
Ascites by Representational Difference Analysis
J.E. Vivienne Watson,1,3 Hani Gabra,1 Karen J. Taylor,1 Genevieve J. Rabiasz,1
Harris Morrison,2 Paul Perry,2 John F. Smyth,1 and David J. Porteous2
1Imperial Cancer Research Fund (ICRF) Medical Oncology Unit and 2Medical Research Council Human Genetics Unit
(MRC HGU), Western General Hospital, Edinburgh EH4 2XU, Scotland
We have performed representational difference analysis (RDA) on DNA from tumor cells and normal fibroblasts
isolated from the ascites of a patient with ovarian cancer. Five of six products of the RDA were homozygously
deleted from the tumor DNA. One of these products has been characterized and identifies a homozygous
deletion of ~ 6.9 Mb at chromosome 9p21 in the original ovarian tumor material. This deletion encompasses
CDKN2A (p16), CDKN2B (p15), and IFN-a. PCR analysis of other tumor cell lines using the novel STS based on
the RDA product has shown it to lie between IFN-a and p16, and to identify the distal extent of a homozygous
deletion in another ovarian cancer cell line. These data provide further evidence for a tumor suppressor locus
distinct from, but mapping close to, p16 on 9p21. Cytogenetic analysis using comparative genomic hybridization
(CGH) performed on the same primary tumor confirmed a loss of material from chromosome 9p. However, the
CGH technique had neither the resolution nor the sensitivity to define a subregion of homozygous loss.
[The GenBank accession no. for this sequence is AF113912.]
Ovarian cancer is the fifth most common cause of
death from cancer among women. It kills 80% of those
5000 diagnosed in the United Kingdom every year, pri-
marily because of its late presentation. The majority of
patients present with stage III and IV disease, for which
the 5-year survival rates are 17% and 5%, respectively
(Chang et al. 1994). It is clear that much more needs to
be understood of the biology of this disease before sig-
nificant advances in current diagnosis and treatment
can be made. At the genetic level, several oncogenes
have been shown to be activated, amplified, or over-
expressed in ovarian cancer, including c-erbB2 (HER2/
neu) (Slamon et al. 1989), Ki-ras, H-ras, c-myc (Yokota et
al. 1986), and c-fms (Bast et al. 1993; for reviews, see
Chuaqui et al. 1997; Steel and Gabra 1997). However,
relatively few recessively acting genes, or so-called tu-
mor suppressor genes, have been directly implicated in
the molecular pathology of ovarian cancer. Mutation
of p53 has been observed in ~ 52% of tumors (Teneri-
ello et al. 1993), nm23 expression has been lost or
changed in 21.7% of tumors (Mandai et al. 1995), and
E-cadherin (CDH1) is mutated in small numbers of
ovarian tumors (Risinger et al. 1994). In familial cases
of ovarian cancer, mutation of BRCA1 has been seen in
only 10% of tumors (Merajver et al. 1995; Takahashi et
al. 1995) and BRCA2 in even fewer (Takahashi et al.
1996).
Loss of both copies of a gene involved in regula-
tion or control of cell growth or proliferation is detect-
able through loss of heterozygosity (LOH) studies. LOH
analyses of ovarian blood/tumor pairs has revealed
many regions of loss in ovarian tumors (for review, see
Black et al. 1998). However, none of these studies has
led directly to the identification of novel tumor sup-
pressor genes. This is in part due to the ambiguous
nature of the results of LOH analyses of ovarian tu-
mors. Contaminating stromal tissue and contradictory
or low-significance results can make it difficult to de-
fine a restricted region in which a novel tumor sup-
pressor gene is located.
For other tumor types, regions of homozygous loss
have proved very valuable for the identification of tu-
mor suppressor genes, as the deletions are discrete and
provide a limited and precise chromosomal interval for
positional cloning. However, to date, the majority of
such genomic lesions described both in ovarian and
other cancers have been in the DNA of tumor cell lines,
which is itself subject to in vitro karyotypic evolution.
Techniques such as fluorescence in situ hybridization
(FISH), Southern analysis, and dense microsatellite
mapping can be used to detect homozygous deletions
in primary tissue containing contaminating normal
tissue (Cairns et al 1995). However, these methods re-
3Corresponding author.
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quire a high density of markers within a limited ge-
nomic region.
The technique of representational difference
analysis (RDA) enables the whole genome of a tumor
sample to be compared to its normal counterpart and,
for regions of loss or amplification, to be isolated di-
rectly. First described by Lisitsyn (1993), the method
uses PCR-generated ‘‘representations’’ of the genomic
DNA starting materials to facilitate kinetic enrichment
of sequences present in only one of the DNA sources.
We have applied the method of RDA to purified
populations of tumor and normal fibroblast cells de-
rived from a specimen of ascitic fluid from a patient
with ovarian cancer, to identify regions of homozy-
gous loss directly from patient material. Malignant
ovarian ascites have been shown to share many of the
histological and antigenic properties of the primary tu-
mor (Hamilton et al. 1983; Provencher et. al 1993) and
should contain genomic rearrangements and deletions
associated with a poorly differentiated, highly malig-
nant cellular phenotype. In most cases reported previ-
ously, RDA has been applied to tumor cell lines and
their normal counterpart. By using primary material,
we avoided cloning sequences that may have been lost
through in vitro karyotypic evolution.
After performing RDA we have isolated and cloned
several novel sequences that were homozygously de-
leted from malignant ascitic cells but were present in
normal fibroblasts. One of the clones maps to 9p21,
and we show that it is derived from a large deletion
that encompasses not only the previously described
tumor suppressor genes CDKN2A/p16 and CDKN2B/
p15 but also other potential tumor suppressor genes.
We have also analyzed the primary material by
CGH to identify gross rearrangements and deletions
within the tumor and to provide a comparison with
results obtained from RDA.
RESULTS
Representational difference analysis of malignant and
fibroblast cells from a patient with ovarian cancer was
carried out. Three rounds of kinetic enrichment were
performed with tumor DNA in 100-fold excess. The
products were subcloned and sequenced (Fig. 1). Six
unique products were examined in more detail; five
were shown by PCR and Southern blot analysis (data
not shown) to be absent from the tumor while being
present in the normal genomic counterpart (Fig. 2),
and therefore lay within a homozygous deletion spe-
cific to the tumor.
PCR on a monochromosome hybrid panel with
primers derived from one of the products, RD55,
showed that it mapped to chromosome 9. PCR with
RD55 on cell lines derived from the original ascites
specimen (PEO1, PEO4, PEO6, PEO1CDDP; see Meth-
ods) confirmed it to be homozygously deleted. PCR
with RD55 on a panel of DNA samples from different
human tumor cell lines showed it to be homozygously
deleted in 2 of 17 cases. Mapping on a radiation hybrid
(RH) panel of chromosome 9 placed the RDA product
between a-interferon (IFN-a) and CDKN2 (p16) with
odds of 1000:1 (Bouzyk et al. 1997).
STS markers from 9p21.3 to pter were used to char-
acterize the deletion in the original primary malignant
ovarian material; the data are summarized in Figure 3.
The same markers were also used to define the extent
of the deletions in the tumor cell lines (Table 1).
The original tumor material and the cell lines de-
rived from it (PEO1, PEO4, PEO6, PEO1CDDP) all had a
deletion that encompassed IFN-a, p16, and p15. This
deletion is flanked by the markers D9S162 and D9S171
and, from the RH map described by Bouzyk et al.
(1997), could be as large as 6.9 Mb.
In addition to those cell lines derived from the
original ascites specimen, 5 of 17 of the independent
tumor cell lines characterized were homozygously de-
leted for p16 exon 2. Deletions of this region in some
of these cell lines have been reported previously
(Chenevix-Trench et al. 1994; Shih et al. 1997), and it
confirms these results. In two of these cell lines, MCF7
Figure 1 RDA results: difference products and cloned products.
(Lanes 1–3) Difference products after first, second, and third
rounds of enrichment. (Lanes a–h) Results of PCR amplification of
inserts of cloned RDA products.
Figure 2 Analysis of RDA products: PCR of original material.
PCR using primers derived from RDA products RD2, RD30, and
RD55 on original fibroblast DNA (F); original tumor material (T);
or genomic DNA from another individual (+); (-) Control reaction
with no template DNA.
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and 59M, the deletion is confined by RD55 distally and
D9S1748 proximally, and does not include p15
(CDKN2B). This distance is estimated to be <400 kb
(Weaver-Feldhaus et al. 1994). Cell line SKOV3 was de-
leted for both p15 and p16, subtended by the markers
D9S966 and RD55. These markers are all contained
within a single CEPH mega-YAC with an estimated in-
sert size of 1200 kb (Bouzyk et al. 1997). OVCAR5 was
shown to be deleted for both p15 and p16 but not
IFN-a. It is deleted for RD55, which places the RDA
product proximal to IFN-a. Toward the centromere,
the deletion in this cell line extends as far as, and in-
cludes D9S966. The next closest marker mapped is
D9S171, which is retained but lies the other side of a
Table 1. PCR Analysis of Markers on Chromosome 9p in Original Tumor and Fibroblast DNA and in Cancer Cell Lines
( ) Marker showing LOH; ( ) marker homozygously lost; ( ) marker uninformative; ( ) marker heterozygous; (1) marker
lost; (+) marker retained. Cell lines boxed in bold are derived from the same patient. Markers derived from coding regions are shown
in boldface type.
Figure 3 Chromosome 9 map. Map of part of human chromosome 9p showing the status of DNA markers and gene sequences in PEO4
tumor DNA. The extent of the homozygous deletion in the ovarian tumor is indicated in bold.
Watson et al.
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gap in the RH map. This deletion could therefore be as
large as 4.6 Mb. The deletion in MDA.MB.231 was
shown to be even larger than that identified in the
original tumor used in the RDA experiment and ex-
tends as far as D9S265 proximally, giving a maximum
size estimate of ~ 9 Mb.
Cytogenetic Analysis
Comparative genomic hybridization analysis of the
original tumor material was carried out (see Methods).
The ratios of fluorescent signal of tumor to normal
DNA revealed multiple copy number abnormalities in
this tumor (Fig. 4a,b). These are summarized in Table 2.
The large homozygous deletion identified through RDA
could be seen as a loss of material from 9pter to 9p12.
DISCUSSION
In 1994, Kamb et al. reported the localization of a
novel tumor suppressor gene to chromosome 9p21
through mapping of homozygous deletions in mela-
noma cell lines. The gene, p16/CDKN2A, was shown to
be homozygously deleted at high frequency in many
other cell lines derived from different tumor types (No-
bori et al. 1994). It was shown to be a member of a
family of cyclin-dependent kinase (CDK) inhibitors
that are important in normal cell-cycle regulation (Ser-
rano et al. 1993).
Conflicting views have been presented however,
as to the importance of p16 as a multitissue tumor
suppressor gene. For example, although 74% of mela-
noma cell lines analyzed had homozygous deletions or
Figure 4 CGH results for PEO4 tumor DNA. (a) A digital image of a typical metaphase. Regions that are over-represented in the tumor
are visualized as predominantly green, whereas regions that are under-represented or deleted from the tumor are seen as predominantly
red. Bar, 10 µm. (b) The quantitative digital image analysis of fluorescence intensity ratios next to a diagram of the chromosome. The
mean ratio (thick line) and 51 S.E. (thin lines) of measurements from n metaphases for each chromosome are shown from pter to qter
(top to bottom). The baseline value (1.0) representing the mean green-to-red ratio for the entire metaphase is shown as a broken line, and
ratios 0.5 and 1.5 as dotted lines. Regions approaching a ratio of 0.5 were taken as losses; regions having a ratio >1.5 were taken as gains.
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intragenic mutations within p16, a frequency of only
19% was observed in primary melanomas, suggesting
that deletions in p16 are necessary for growth of mela-
noma cells in culture and may not be so important in
carcinogenesis in vivo (Walker et al 1998).
Despite the reported high levels of LOH at 9p21 in
many different tumors (Caldas et al. 1994; Puig et al.
1995; Williamson et al. 1995), the inactivation of the
second allele of p16 through microdeletion or point
mutation as predicted by Knudson’s two-hit hypoth-
esis has only been found in a limited number of tumor
types, predominantly those of the pancreas (Caldas et
al. 1994). However, homozygous deletions have been
found in a growing number of primary tumors of dif-
ferent tumor types in the 9p21 region that harbors this
gene (Cairns et al. 1995), suggesting that this is the
predominant mechanism for gene loss. There is also
evidence for inactivation of the second copy of the
gene by methylation in some common cancers (Her-
man et al. 1995; Merlo et al. 1995), although this does
not include ovarian carcinoma.
Although relatively high levels of homozygous de-
letion have been reported in ovarian tumor cell lines—
4/8 (Rodabaugh et al. 1995) and 5/11 (Shih et al.
1997)—the frequency of homozygous deletions of this
region reported in primary ovarian cancers is low—2/
88 (Shih et al. 1997) and 1/67 (Campbell et al. 1995).
Some groups claim higher frequencies of homozygous
loss in primary tumors detected through multiplex
PCR analysis (Ichikawa et al. 1996). However, LOH for
this region is relatively high—48% (Campbell et al.
1995) and 45% (Chenevix-Trench et al. 1997)—but the
number of gene-inactivating point mutations found in
p16 in tumors with LOH is very small (Rodabaugh et al.
1995; Schultz et al. 1995). In addition no studies so far
have detected inactivation of p16 by methylation in
ovarian tumors (Ichikawa et al. 1996; Shih et al. 1997).
Taken together, these data imply the involvement of
another locus located around 9p21 in the genesis of
ovarian cancer. A failure to find inactivation of either
p16 or p15 in cutaneous malignant melanoma in
which LOH frequencies are high also suggests that
there may be another potential tumor suppressor gene
in the region (Puig et al. 1995).
Our results from the analysis of ovarian cell lines
and primary malignant ovarian tumor cells agree with
a hypothesis for an additional tumor suppressor gene
at 9p21. In several of the cell lines characterized
(OVCAR5, PEOs), the homozygous deletions extend
for a large distance beyond the defined tumor suppres-
sor genes p16 and p15. Interestingly the deletion de-
tected in primary malignant ascites cells by RDA also
extended across the same region, strengthening the
case for the involvement of this additional gene in car-
cinogenesis in vivo.
The possible candidate gene IFN-a is excluded, as
IFN-a is retained in OVCAR5 and the distal extent of
the deletion is defined by RD55. This suggests that a
novel tumor suppressor may lie either within the 400-
kb region distal to p16 limited by the novel RDA prod-
uct RD55, or within 2.8 Mb proximal to p16, defined
by the marker D16S171. Loss of function of this novel
gene may account for the high frequency of LOH ob
served at 9p21 in ovarian tumors that do not show inac-
tivation of p16 by deletion, mutation, or methylation.
CGH analysis of DNA from the malignant ascites
of tumor PEO4 reveals multiple regions of amplifica-
tion and loss. A total of 20 copy number abnormalities
(CNAs) were identified (see Table 2). There is a clear
reduction in the ratio of green to red signal on 9p, from
9pter up to and including 9p21. This region covers the
homozygous deletion detected by RDA at 9p21.3, but
the loss of both copies of the chromosome at this point
cannot be distinguished from the immediate proximal
and distal regions, which we know to be conserved
within the tumor from STS mapping (see Fig. 3). The
size of the deletion on 9p21, detected by RDA at ~ 7 Mb,
is outside of the limits of resolution of CGH. This result
highlights the limitations of CGH in the detection of
biologically significant chromosomal deletions.
To our knowledge, this is the first report of CGH
analysis of malignant ovarian ascites. The degree of
CNA in this tumor demonstrated by CGH analysis is
not unusual for an advanced stage ovarian epithelial
carcinoma. Iwabuchi et al. (1995) report CNAs of be-
tween 0 and 30 in 44 different ovarian tumors, with
high-grade tumors exhibiting, on average, more abnor-
malities than lower grade tumors. Twenty-three of the
24 well or moderately differentiated epithelial ovarian
carcinomas analyzed by Tapper et al. (1997) show CNA
ranging from 1 to 17, and Wolff et al. (1997) report
CNAs of between 1 and 31 in their panel of 24 ovarian
carcinomas of different subtypes. Of the 17 distinct
CNAs we observed in PEO4, most have been observed
previously, including gains at 8q23–8q24, 11q13, and
17q22–qter and losses at 4q22–qter, 5p14, 6q16–qter,
Table 2. Summary of Chromosomal Gains and Losses
Observed by CGH on PEO4 Tumor DNA
Chromosome gains Chromosome losses
4p15 1q32.2–qter
8q23–8q24 4q22–qter
11q13 5p14
17qter 6q16–qter
7p14–21
9pter–p21, 9q21, 9q22.3–33
11p15–pter
13q
16q22–qter
17p, 17q12
18q22–qter
22q13–qter
X
Watson et al.
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9pter–p21, 13q, 16q22–qter, 17p, 17q12, 18q22–qter,
and X. The following gains and losses of material had
not been reported previously: +4p15, 19q21,
19q22.3–33, 111p15–pter, and 122q13–qter.
RDA has been used previously in the identification
of homozygous deletions that have led toward the
cloning of several novel tumor suppressor genes in-
cluding BRCA2 (Schutte et al. 1995; Wooster et al.
1995), FHIT (Ohta et al. 1996), and MMAC/PTEN (Li et
al. 1997; Steck et al. 1997). When we performed RDA
on primary ovarian tumor DNA, five distinct products
were isolated that were shown to be homozygously de-
leted from the tumor but retained within the fibroblast
DNA from the same patient. One of these products has
been shown to be part of a large homozygous deletion
of chromosome 9p21, which encompasses IFN-a, p16,
and p15 and possibly one or more additional uniden-
tified tumor suppressor genes. We hope that character-
ization of the other four RDA products will lead to the
identification of other novel loci that house tumor
suppressor genes involved in ovarian cancer.
METHODS
Clinical Material
An ascites specimen was taken from a patient with advanced
serous epithelial ovarian cancer. The cell line PEO1 was de-
rived from the malignant cells in this sample (Wolf et al.
1987). Ascites taken from the patient after relapse some 10
months later was used to derive the cell lines PEO4, PEO6, and
PEO1CDDP as described previously (Wolf et al. 1987; Langdon
et al. 1988). An additional sample of ascites was cultured and
trypsin/versene added until the fibroblast cells just became
detached. These fibroblast cells could then be removed selec-
tively and cultured separately. Several rounds of differential
trypsinization were performed until distinct and pure fibro-
blast and tumor cell populations were obtained. DNA was
isolated from the two cell types (Nucleon DNA extraction kit,
ScotLab), and it was from these samples that representations
were derived for the difference analysis procedure.
Cell lines
PEO14, PEO16, PEO23, PEA1, and PEA2 are all cell lines de-
rived from epithelial ovarian tumors (Wolf et al. 1987; Lang-
don et al. 1988); PEA1 and PEA2 are derived from the same
patient. OVCAR3, OVCAR4, OVCAR5, A2780, 59M, OAW42,
OAW28, and SKOV3 are all human ovarian cancer cell lines
obtained from the American Tissue Culture Collection
(ATCC). HeLa Ohio was a gift from A. Cranston (Queen’s Uni-
versity, Belfast, UK); HCT116, a colorectal cancer cell line, was
a gift from S. Farrington (MRC–HGU), ZR75.1, MCF7, and
MDA.MB.231 are breast cancer cell lines available from the
ATCC.
RDA
RDA was performed exactly as described by Lisitsyn et al. 1993
(a detailed protocol was supplied by N. Lisitsyn and has now
been published in Lisitsyn and Wigler 1995).
Briefly, 2 µg of DNA from the two cell populations was
digested with BglII and then ligated to the first primer pair set
(R Bgl 24 and R Bgl 12) that had been annealed previously. R
Bgl 24 was used as a primer for PCR on 40 ng of the catch-
linkered templates, to generate tester (fibroblast) and driver
(tumor) amplicons. The first set of catch linkers was removed
from the amplicons by restriction endonuclease digestion
with BglII. The tester amplicon was gel-purified and the DNA
re-extracted from the agarose using a Qiaquick gel extraction
kit (Qiagen Ltd., Crawley, UK). One microgram of purified
tester amplicon was ligated to annealed primer pair set 2 (J Bgl
24 and J Bgl 12). Subtractive hybridization was performed
using 40 µg of the prepared driver amplicons and 400 ng of
the prepared tester. Selective amplification of self-reannealed
tester fragments was carried out by performing 10 cycles of
PCR using J Bgl 24 as a primer. This produced the first-round
difference product. Remaining single-stranded DNA (ss-DNA)
molecules were removed by digestion with mung bean nucle-
ase (New England Biolabs), before performing a further 20
cycles of PCR. Linkers were removed from the first-round dif-
ference product again by digestion with BglII. The third
primer pair set of annealed oligonucleotides (N Bgl 24 and N
Bgl 12) was ligated to the digested difference product. A fur-
ther two rounds of subtractive hybridization and selective am-
plification were carried out, using primer pair set 2 as catch
linkers on the second-round product to generate the third
round difference product.
Cloning of RDA Products
Products of the final round of PCR were digested with BglII
and shotgun-cloned into BglII-digested, dephosphorylated
pBS plasmid vector (Stratagene), a gift from Tony Brookes
(MRC–HGU). Cloned products were sequenced using T3 and
T7 as primers in either a dideoxy sequencing reaction (Se-
quenase) with 35S incorporation, or they were cycle-
sequenced using Taq FS fluorescent dideoxy termination mix
(ABI), and then analyzed on a 373 automated ABI sequencing
apparatus.
PCR Analysis
Specific PCR primers were derived from the sequences. For
RDA product RD55, these were 58-TACAACAGGAT-
CAAGAAGGC-38 and 58-AGAGAAACCGAGAAGAAACC-38.
PCR conditions were as follows: 50 ng of template, 300 ng of
primer, 50 mM KCl, 10 mM Tris (pH 9), 0.1% Triton X-100, 1.5
mM MgCl2, 200 µM dNTPs, and 1 unit of Taq Polymerase
(ICRF). Cycling conditions were as follows: 93°C for 1 min
21; 70°C for 30 sec, 72°C for 30 sec, 91°C for 30 sec 22; 68°C
for 30 sec, 72°C for 30 sec, 91°C for 30 sec 22; 66°C for 30 sec,
72°C for 30 sec, 91°C for 30 sec 22; 64°C for 30 sec, 72°C for
30 sec, 91°C for 30 sec 22; 62°C for 30 sec, 72°C for 30 sec,
91°C for 30 sec 22; 60°C for 30 sec, 72°C for 30 sec, 91°C for
30 sec 220; 72°C for 5 min.
Human monochromosome somatic cell hybrid panel
was from the HGMP Resource Centre (Hinxton, Cambridge,
UK). STS markers p16 exon 2, p15 exon 2, and c.1b were a
kind gift from Kathy Williamson (MRC HGU) and are de-
scribed in Kamb et al. (1994). Primers for IFN-a and TYRP1
were a gift from Cathy Abbot (University of Edinburgh, UK)
(sequence is held by GenBank). Primers for other STS mark-
ers—D9S288, D9S178, D9S285, D9S156, D9S157, D9S162,
D9S1749, D9S1748, D9S1752, D9S942, D9S171, D9S265,
D9S272, D9S176, D9S1748, D9S1747, D9S942, and
Homozygous Deletion on Human Chromosome 9p21
Genome Research 231
www.genome.org
 Cold Spring Harbor Laboratory Press on March 23, 2014 - Published by genome.cshlp.orgDownloaded from 
D9S1752—were synthesized by ICRF support services accord-
ing to the sequences held in GenBank.
CGH
CGH analysis was carried out on metaphase spreads prepared
from an unsynchronized culture of fresh phytohemaglutinin-
stimulated lymphocytes from a healthy male (46XY) using
standard procedures of hypotonic treatment and methanol/
acetic acid fixation (3:1). Total genomic tumor DNA and nor-
mal total genomic DNA were labeled by nick translation with
fluorochrome-conjugated nucleotides FITC11–dUTP (Amer-
sham, UK) and Texas Red–5-dUTP (Dupont, Boston, MA), re-
spectively. Another sample of total genomic DNA from a nor-
mal female was labeled with FITC-11–dUTP as a control. The
size of the resultant labeled DNA fragments was checked as
being in the range of 600–1700 bp.
Hybridization experiments were carried out as described
previously (Kallioniemi et al. 1994) with minor modifica-
tions. Briefly, normal lymphocyte metaphase chromosomes
were prepared by incubation at 37°C in 100 µg/ml RNase, 22
SSC for 1 hr. They were then dehydrated through an ethanol
series (70%, 90%, 100%) and denatured in 70% formamide/
22 SSC at 70°C for 3 min. After quenching in cold 70% etha-
nol, the dehydration was completed by passing slides through
90% and 100% ethanol.
Equal amounts of previously labeled tumor and normal
DNA (400 ng), together with 5 µg of unlabeled Cot1 DNA
(GIBCO), was precipitated, dried, and resuspended in 10 µl of
hybridization mix (50% formamide, 10% dextran sulfate, 22
SSC, 0.1% Tween 20). This was then denatured at 70°C for 5
min and applied immediately to the lymphocyte metaphase
preparations. After hybridization at 37°C for 48 hr the slides
were washed four times for 3 min in each of 50% formamide/
22 SSC, and 22 SSC at 45°C and in 0.12 SSC at 60°C. The
slides were then transferred to 42 SSC/0.1% Tween 20 and
counterstained with 1.5 µg/ml DAPI in Vectashield antifade
solution (Vector Labs, Peterborough, UK).
The slides were analyzed using a Zeiss Axioplan micro-
scope equipped with a CCD camera and a filter system. Exci-
tation of the individual fluorochromes was done by means of
a single band pass excitation filter in a computer-controlled
wheel. The information was processed using a Sun Sparc10
workstation and the red-to-green ratios were calculated using
X-woolz software developed by J. Piper (Piper et al. 1995).
Twenty-five to 30 metaphases were captured, and the fluores-
cence ratios for each chromosome type were derived from the
three color images. The chromosomes were digitally seg-
mented and the interchromosomal background removed
from the chromosomal fluorescence. The fluorescence inten-
sities along the length of all the chromosomes in each meta-
phase were then calculated and normalized so that the overall
green-to-red ratio for each metaphase was 1.0. Thereafter, a
drop in standard deviation below 1.0 was defined as a loss in
DNA copy number and a rise above 1.0 as a gain in that
particular region of the tumor genome. Only images that
showed a uniform fluorescence in both green and red signal
across the metaphase were analyzed.
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